Navigation Links
Genelux Corporation Appoints Jodi Devlin as President
Date:1/12/2011

SAN DIEGO, Jan. 12, 2011 /PRNewswire/ -- Genelux Corporation, a privately held, San Diego-based biopharmaceutical company developing novel therapies against cancer, today announced that its Board of Directors has appointed Jodi Devlin as the company's President effective January 10, 2011.  Dr. Aladar Szalay, the company's Founder, will continue to serve as CEO and Chairman of the Board.

"Ms. Devlin is an excellent choice to lead Genelux Corporation into the next phase of growth, from commercializing the Company's leading cancer therapy to transforming the Company's operations accordingly," said Dr. Aladar Szalay, Founder, Chairman and CEO.  "She brings two decades of extensive commercialization and executive management experience at one of the world's leading pharmaceutical companies to Genelux and has the vision and energy to help us realize our goals."

Ms. Devlin's experience spans a broad range of functions including commercialization, clinical development, strategic business development and planning.  Most recently, Ms. Devlin served as Vice President at Abbott where she led Global Pipeline Marketing for all therapeutic areas, including oncology.  Over the course of her career, Ms. Devlin held positions as Vice President of International Marketing, U.S. Specialty Operations, Primary Care and Virology.  Under her leadership, HUMIRA®, Kaletra® and TriCor® all achieved multi-billion dollar status.  Ms. Devlin holds a BS in Nursing from the University of Oklahoma and an MBA from Washington University Olin School of Business.

"We are very pleased that Ms. Devlin will be joining our team at an exciting time in the company's evolution," said Dr. Szalay. "Her proven leadership and management capabilities have prepared her well for this new challenge.  She is a competent professional and knows how to bring a product successfully to market.  We believe she has the right combination of experience, results-orientation and talent to grow and build Genelux Corporation. "

"Having served on the search committee, I had the opportunity to evaluate a number of strong candidates.  Ms. Devlin stood out as our top choice," said Dr. Albert Roeder, COO and a member of the company's Board of Directors. "Her skill set richly complements our current capabilities and strengthens our future commercialization plans."

"It is an honor to join Genelux Corporation as the company's first President," said Ms. Devlin. "I am excited to help bring such innovative and potentially life-saving technology to cancer patients and to rapidly advance the company's tremendous portfolio of therapeutics and diagnostics.  I look forward to working with Dr. Szalay, the Board of Directors, and our management team for the benefit of cancer patients while generating value for our shareholders.  In addition, I will continue to build upon the positive and rewarding environment for our employees."

About Genelux Corporation

Genelux Corporation was founded in 2001 with a mission to develop safe and effective diagnostic and therapeutic solutions for cancer and inflammatory diseases for which there are no effective treatments today. Genelux Corporation is headquartered in San Diego, California,

Genelux Forward Looking Statement

Statements made about Genelux Corporation, other than statements of historical fact, reflect Management's current beliefs and assumptions founded on the data and information currently available to us. Statements of the company's progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, patents, inception and/or continuation of corporate and other strategic partnerships and the need for additional funding or financing.  


'/>"/>
SOURCE Genelux Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio
2. Neogen Corporation Announces 2nd Quarter Results Conference Call
3. China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on February 18, 2011
4. China Cord Blood Corporation Announces Completion of Warrant Exchange
5. China Cord Blood Corporation Announces Participation at the 29th Annual J.P. Morgan Healthcare Conference
6. Intel Corporation acquires Toronto start-up CognoVision
7. Celladon Corporation Announces MYDICAR® Enzyme Replacement Therapy for Advanced Heart Failure Provides Sustained Clinical Improvements in Patients for 12 Months Compared with Placebo
8. Sigma-Aldrich Corporation Announces Death of Chairman and CEO; Election of New CEO and Chairman; Conference Call Scheduled for 10:00a.m. (Central Time) on November 15, 2010
9. International Technidyne Corporation Acquired by Warburg Pincus
10. Omeros Corporation Awarded $1.7 Million in Grants Under the Qualifying Therapeutic Discovery Project Program
11. NEURO-BIOTECH CORPORATION: Updates and latest developments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
Breaking Biology Technology:
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)... 15, 2016 Research and ... Biometrics Market 2016-2020,"  report to their offering.  , ... , ,The global gait biometrics market is expected ... the period 2016-2020. Gait analysis generates ... be used to compute factors that are not ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):